RxE2

Executive Summary

RxE2 is transforming clinical trial execution by deploying a hub-and-spoke model that leverages independent community pharmacies as decentralized trial sites. This approach addresses the primary cause of clinical trial delays—patient recruitment and retention, which accounts for 80% of delays. By utilizing trusted local pharmacists, RxE2 enhances patient access, reduces travel burden, and improves diversity in trial populations. The model enables sponsors to accelerate enrollment timelines, lower operational costs, and increase data real-world relevance. With a focus on community-based care, RxE2 is poised to become a critical infrastructure provider for the rapidly growing decentralized clinical trial market.

Upcoming Catalysts (preview)

• Q3 2026Major Pharma Partnership65% success
• Q4 2026Pilot Study Results Publication80% success
• Q1 2027Series A Funding Announcement60% success